An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Trial Status: active
A first in human study to evaluate the safety and preliminary antitumor activity of
BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or
metastatic KRAS mutant solid tumors.
Inclusion Criteria
Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation, or KRAS-amplification
Measurable disease by RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
Exclusion Criteria
Malignancy within the last 2 years as specified in the protocol
Untreated brain metastases
Known hypersensitivity to BBO-11818 or its excipients Other inclusion/exclusion criteria are specified in the protocol.
Additional locations may be listed on ClinicalTrials.gov for NCT06917079.
Locations matching your search criteria
United States
California
La Jolla
UC San Diego Moores Cancer Center
Status: Active
Name Not Available
Florida
Tampa
Moffitt Cancer Center
Status: Active
Name Not Available
Massachusetts
Boston
Massachusetts General Hospital Cancer Center
Status: Active
Name Not Available
Texas
Houston
M D Anderson Cancer Center
Status: Active
Name Not Available
Utah
Salt Lake City
Huntsman Cancer Institute/University of Utah
Status: Active
Name Not Available
This is an open-label, multi-center, Phase 1 study designed to evaluate the safety,
tolerability, pharmacokinetics, and efficacy of BBO-11818, a pan-KRAS inhibitor, alone
and in combination with pembrolizumab, pembrolizumab +/- cis/carboplatin + pemetrexed, or
cetuximab in subjects with locally advanced unresectable or metastatic KRAS mutant solid
tumors. The study includes dose escalation phase and dose expansion phase.
Trial PhasePhase I
Trial Typetreatment
Lead OrganizationTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
